A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
What are clinical trials for pulmonary fibrosis?
Clinical trials for pulmonary fibrosis are research studies used to evaluate new treatments, therapies, or diagnostic methods for pulmonary fibrosis, a group of lung diseases characterized by scarring and inflammation of lung tissue. Pulmonary fibrosis clinical trials aim to find more effective ways to manage the disease, improve symptoms, and enhance quality of life for patients living with the disease.
They may involve testing new drugs, biologics, or treatment combinations, as well as exploring novel approaches like gene therapy or stem cell therapy. Clinical trials for pulmonary fibrosis can also assess new diagnostic tools or methods to detect the disease earlier or monitor its progression more accurately.
Why are clinical trials for pulmonary fibrosis important?
Although pulmonary fibrosis is considered a rare disease, it is still thought that up to 58,000 new cases are established every year in the US. Hence, clinical research into the disease is highly important. Pulmonary fibrosis clinical trials are important for advancing the development of new and more effective treatments for people with the condition, who may currently have limited therapeutic options and impacted quality of life.
These clinical trials help researchers evaluate novel drugs, therapies, and interventions that may slow disease progression, reduce symptoms, or improve lung function. They also contribute to a better understanding of the mechanisms of pulmonary fibrosis and identify potential biomarkers for earlier diagnosis.
Types of pulmonary fibrosis clinical trials
When choosing which type of trial design to use for a clinical study on pulmonary fibrosis, researchers have a variety of options to choose from. They may opt for any one of the following trial types depending on the objectives of the study.
Genetic and biomarker studies
Researchers often use genetic and biomarker studies for pulmonary fibrosis to focus on understanding the genetic factors and biological markers that influence the disease’s development, progression, and response to treatment. Specific genetic mutations or variations may be investigated to identify biomarkers such as proteins, cells, or molecules in blood or tissue samples that are commonly associated with pulmonary fibrosis.
Genetic and biomarker studies are essential for uncovering underlying mechanisms of the pulmonary fibrosis, predicting disease risk, and personalizing treatment approaches based on individual genetic profiles and biomarker patterns. Integrating these findings means researchers can develop targeted therapies and improve diagnostic accuracy, ultimately enhancing patient care and treatment outcomes.
Interventional trials
Interventional studies in clinical trials for pulmonary fibrosis involve administering experimental treatments or therapies to evaluate their effectiveness and safety. These studies are designed to test new drugs, biologics, or combinations of existing treatments to determine their impact on disease progression, symptom management, and lung function.
The goal of interventional studies is to identify more effective therapies that can slow the progression of pulmonary fibrosis, improve patients' quality of life, and provide new options for managing this challenging condition.
Prevention trials
Prevention trials in clinical research for pulmonary fibrosis focus on identifying strategies to prevent the onset or progression of the disease, particularly in individuals at high risk or those showing early signs. These trials may test interventions such as medications, lifestyle changes, or other preventive measures. By evaluating these preventive approaches, the trials aim to find effective ways to delay or prevent the disease from worsening, thereby improving long-term outcomes and quality of life for individuals susceptible to pulmonary fibrosis.
Participation in a pulmonary fibrosis clinical trial
Deciding to participate in a clinical trial for pulmonary fibrosis takes a lot of consideration. While there are some risks involved with clinical trials, there is also the potential to experience considerable benefits.
Participant benefits
There are several benefits of participating in a clinical trial for pulmonary fibrosis, including gaining access to innovative treatments and therapies that may not yet be available outside the trial environment. Participants will receive close monitoring and specialized care from medical experts, which can lead to early detection of side effects and more personalized treatment adjustments.
Additionally, involvement in a pulmonary fibrosis clinical trial provides an opportunity to contribute to critical research that advances understanding of pulmonary fibrosis and helps develop better future treatments. For some participants, these new therapies might improve symptoms and quality of life, offering potential benefits beyond current standard treatments.
Risks and considerations
Participating in a clinical trial for pulmonary fibrosis involves several risks and considerations, such as the potential for experiencing unknown side effects from experimental treatments. There is no guarantee that the new treatment will be effective or that it will improve symptoms, and it might even worsen the condition. This can be difficult for participants with later stages of the disease who could be hopeful for a successful treatment.
Participants may also need to adhere to strict schedules for medical visits, tests, and treatments, which can affect their daily life and be time consuming. There might also be uncertainties regarding coverage of trial-related costs and the emotional stress of navigating experimental therapies. Despite these risks, many are motivated by the opportunity to access cutting-edge treatments and contribute to important research.
Who can participate in a clinical trial for pulmonary fibrosis
Those diagnosed with pulmonary fibrosis or at high risk of developing it are often prime candidates for a clinical trial studying the condition. However, eligibility criteria for each clinical trial will vary depending on the study objectives.
Researchers may also consider factors such as the type and severity of pulmonary fibrosis, overall health, age, and previous treatments. Some trials may target specific subgroups too, such as patients with particular symptoms, genetic profiles, or levels of lung function impairment. In some cases, healthy volunteers may be included for comparison purposes.
Unsure about participating in clinical trials? Dive into our comprehensive guide to learn about the process, benefits, and potential impact of your involvement. Get the facts you need to make an informed decision today!
What to expect when participating in a pulmonary fibrosis clinical trial
When participating in a clinical trial for pulmonary fibrosis, you can expect to undergo a comprehensive screening process to determine your eligibility. You’ll also need to provide informed consent, which ensures you understand the trial’s objectives, procedures, risks, and benefits. If you are eligible and accepted, you will begin treatment which will vary depending on the study design.
In any clinical trial type, you will be closely monitored through regular medical visits, tests, and assessments to either evaluate the treatment's effectiveness and safety or establish other outcomes. You may also have to adhere to strict trial protocols as part of your involvement, which could involve lifestyle changes, restrictions, additional activities, and other requirements.
How to enroll in a pulmonary fibrosis clinical trial
Enrolling in a clinical trial studying pulmonary fibrosis through our platform is a straightforward and user-friendly process. Here's how to get started:
- Identify Your Trial: Use our intuitive search bar or filter options to locate clinical trials specific to requirements. This first step simplifies the process of finding relevant research studies tailored to your needs.
- Select Your Preferred Location: To find trials conveniently located near you, simply input your preferred location into the dedicated filter bar on the left-hand side of the page.
- Explore Study Details: For in-depth information about each study, simply click the “Learn More” button. This will provide you with comprehensive details about the trial, including objectives, procedures, and eligibility criteria.
- Complete the Health Profile: After clicking on the “Get started” button you will be taken to our efficient 5-step application process to provide important health information. This helps us match you with the clinical trial that best fits your needs.
- Submit the Application: After completing the application, send it in. A clinical trial coordinator will review it and contact you regarding the possibility of participation.